Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

KITE-363

Drug and asset intelligence for KITE-363 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

Kite Pharma →

Recent signals(1)

ClinicalJuly 5, 2026

KITE-363 Phase 1 Study Initiated for Autoimmune Neurologic Diseases

Kite, Gilead Company, is conducting Phase 1 study to evaluate the safety and efficacy of KITE-363 in patients with relapsed/refractory autoimmune neurologic diseases.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— KITE-363

Key milestones include the determination of the recommended dose and preliminary efficacy results from the Phase 1 trials.

July 5, 2026 · N/A

Indications

Autoimmune Diseases →

Therapeutic areas

Autoimmune Diseases →

Neurology · Autoimmune Diseases →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.